數位基因組市場規模、佔有率、成長分析、按產品、按應用、按最終用戶、按地區 - 按行業預測，2024-2031 年

2022年全球數位基因組市場規模為255億美元，從2023年的294億美元成長到2031年的918.3億美元，預測期內（2024-2031年）複合年成長率為15.3。

在基因組和生物資訊技術進步的推動下，全球數位基因組市場正在經歷強勁成長。最近的分析顯示市場規模和成長潛力顯著擴大，反映了不斷變化的趨勢和競爭格局。這種快速成長的主要驅動力是次世代定序儀(NGS) 技術的日益普及。次世代定序儀能夠提供快速且經濟高效的 DNA 和 RNA 定序，徹底改變了基因組學。隨著 NGS 相關成本持續下降，基因組定序變得越來越容易實現，從而導致產生的基因組資料量顯著增加。這種可訪問性可能會鼓勵數位基因組學領域的進一步創新和應用，從而實現持續發展。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

數位基因組市場規模：依產品分類

• 市場概況
• 定序和分析設備
• DNA/RNA分析套件
• 定序晶片
• 定序和分析軟體
• 樣品製備設備

數位基因組市場規模：依應用分類

• 市場概況
• 臨床
• 生殖健康
• 腫瘤學
• 其他
• 法醫學
• 藥物發現與開發
• 其他用途

數位基因組市場規模：依最終用戶分類

• 市場概況
• 醫院
• 診斷中心和法醫學實驗室
• 調查機構
• 其他最終用戶

數位基因組市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Illumina, Inc.（USA）
• 23andMe, Inc.（USA）
• BGI Genomics Co., Ltd.（China）
• Thermo Fisher Scientific（USA）
• Agilent Technologies（USA）
• Danaher Corporation（USA）
• Oxford Nanopore Technologies plc.（United Kingdom）
• PacBio（USA）
• QIAGEN（Netherlands）
• Roche Holding AG（Switzerland）
• Myriad Genetics, Inc.（USA）
• Invitae Corporation（USA）
• Color Genomics（USA）
• Sema4（USA）
• Veritas Genetics（USA）
• Helix（USA）
• 24Genetics（Spain）
• Dante Genomics（Italy）
• Gencove（USA）
• Nebula Genomics（USA）

結論和建議

Global Digital Genome Market size was valued at USD 25.5 billion in 2022 and is poised to grow from USD 29.4 billion in 2023 to USD 91.83 billion by 2031, growing at a CAGR of 15.3% during the forecast period (2024-2031).

The global digital genome market is experiencing robust growth, propelled by advancements in genomics and bioinformatics technologies. Recent analyses indicate a considerable expansion in market size and growth potential, reflecting evolving trends and the competitive landscape. A significant driver behind this surge is the rising adoption of next-generation sequencing (NGS) technologies, which have transformed genomics through their ability to deliver rapid, cost-effective DNA and RNA sequencing. As the costs associated with NGS continue to decline, genomic sequencing has become increasingly accessible, resulting in a substantial increase in genomic data generation. This accessibility is likely to foster further innovations and applications within the digital genome sector, positioning it for continued advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Digital Genome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Genome Market Segmental Analysis

Global Digital Genome Market is segmented by product, application, end user and region. Based on product, the market is segmented into sequencing and analyzer instruments, DNA/RNA analysis kits, sequencing chips, sequencing and analysis software and sample preparation instruments. Based on application, the market is segmented into clinical, reproductive health, oncology, others, forensics, drug discovery and development and other applications. Based on end user, the market is segmented into hospitals, diagnostic centers and forensic labs, research institutes and other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Digital Genome Market

The global digital genome market is significantly driven by the rising incidence of genetic disorders, which underscores the urgent need for efficient solutions that facilitate accurate diagnosis and timely intervention. As genetic disorders become more prevalent, digital genome technologies are gaining prominence for their ability to provide precise genetic testing, screening, and diagnosis. These advancements enable healthcare professionals to detect genetic conditions early, implement preventive measures, and offer targeted treatments, thereby improving patient outcomes and fostering a proactive approach to healthcare. The demand for such innovative tools is growing rapidly, highlighting the importance of digital genome solutions in modern medicine.

Restraints in the Global Digital Genome Market

The Global Digital Genome market faces several significant restraints, particularly concerning ethical and legal issues. The collection and use of genomic data bring forth complexities surrounding data ownership, informed consent, and the risk of discrimination against individuals. It is essential to navigate these challenges thoughtfully to ensure that ethical considerations do not hinder innovation. Achieving a harmonious balance between promoting technological advancements and addressing these critical ethical concerns will be vital for the sustainable development of the digital genome market. Without careful attention to these restraints, the market's growth may be jeopardized, limiting its potential benefits for society.

Market Trends of the Global Digital Genome Market

The Global Digital Genome market is witnessing significant growth, primarily driven by the rapid adoption of next-generation sequencing (NGS) technologies. These advanced sequencing tools offer unparalleled speed, accuracy, and cost-effectiveness, making genomic analysis accessible to a broader audience, including academic institutions, healthcare providers, and biotechnology companies. As the demand for personalized medicine and targeted therapies increases, organizations are increasingly leveraging NGS for applications in genomics research, clinical diagnostics, and drug development. Moreover, the integration of artificial intelligence and big data analytics in genomic data interpretation is further propelling market expansion, positioning the digital genome sector at the forefront of biotechnological innovation.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Digital Genome Market Size by Product & CAGR (2024-2031)

• Market Overview
• Sequencing and Analyzer Instruments
• DNA/RNA Analysis Kits
• Sequencing Chips
• Sequencing and Analysis Software
• Sample Preparation Instruments

Global Digital Genome Market Size by Application & CAGR (2024-2031)

• Market Overview
• Clinical
• Reproductive Health
• Oncology
• Others
• Forensics
• Drug Discovery and Development
• Other Applications

Global Digital Genome Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Diagnostic Centers and Forensic Labs
• Research Institutes
• Other End Users

Global Digital Genome Market Size & CAGR (2024-2031)

• North America (Product, Application, End User)
  • US
  • Canada
• Europe (Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 23andMe, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PacBio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Color Genomics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sema4 (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veritas Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helix (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 24Genetics (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dante Genomics (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gencove (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nebula Genomics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations